Delivery Order SPE2DB25D3022-SPE2DB25FWCHF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, valued at $52,706.28, is scheduled for completion by August 12, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. The contract received no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Humira (cf) Pen 40 mg/0.4 mls, a pharmaceutical product used primarily for the treatment of inflammatory conditions. This firm fixed price delivery order, valued at $1,510.60, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,041.38 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract utilized competitive procurement procedures with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $2,265.90 and a firm fixed price. The delivery order is scheduled for completion by August 4, 2025, with performance taking place at the company's corporate office in Conshohocken, Pennsylvania. This award utilized no set-aside designation and was competitively awarded through the company's existing contract vehicle. HUMIRA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of rheumatologic and inflammatory conditions. This firm fixed-price delivery order, valued at $17,500.86, represents a non-competitive set-aside contract and is scheduled for completion by August 12, 2025. The contract will be performed at the vendor's Corporate Office location in...
- The Defense Logistics Agency awarded a $2,265.90 delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 MG/0.8 MLS, a pharmaceutical product used in the treatment of autoimmune conditions. This contract, awarded on August 19, 2025, represents a firm fixed price delivery order with an ultimate completion date of August 20, 2025. The award was made through open competition with no set-aside designation, and the product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL medication. This is a firm fixed-price delivery order valued at $33,364.14, with an ultimate completion date of July 22, 2025. The award carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of rheumatoid arthritis and other inflammatory conditions. This firm fixed price delivery order, valued at $2,525.25, was awarded on August 4, 2025, with an ultimate completion date of August 5, 2025. The contract is classified as a non-set-aside competitive award and will be performed at the contractor's location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat inflammatory conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $25,380.93 and is scheduled for completion by July 29, 2025. The contract utilizes no set-aside designations and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,030.54 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a medication used to treat autoimmune conditions. This firm fixed price delivery order, with an ultimate completion date of August 12, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB25D3022Indefinite Delivery Contract
- SPE2DB25D3022-SPE2DB25FWCHFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used primarily for treating rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order has a ceiling value of $2,598.96 and an ultimate completion date of August 20, 2025. The award was made without a set-aside designation, indicating it was awarded through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999.999 billion value through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a wide range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's extensive federal contract portfolio and competitive award history demonstrate the company's established capability to meet DLA medical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/19/25 |